E
Elena Nikiphorou
Researcher at King's College London
Publications - 263
Citations - 3444
Elena Nikiphorou is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 172 publications receiving 1849 citations. Previous affiliations of Elena Nikiphorou include Leiden University Medical Center & New Cross Hospital.
Papers
More filters
Journal ArticleDOI
Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts
Elena Nikiphorou,Lewis Carpenter,Sam Norton,Stephen Morris,Alex J. MacGregor,Josh Dixey,Peter Williams,Patrick A. Kiely,David A. Walsh,Adam Young +9 more
TL;DR: It is suggested that attention to non-inflammatory factors in addition to suppression of inflammation is needed to minimise the burden of orthopaedic surgery.
Journal ArticleDOI
Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force.
Erika Mosor,Paul Studenic,Alessia Alunno,Ivan Padjen,W. Olsder,Sofia Ramiro,Ilaria Bini,N Caeyers,Laure Gossec,Marios Kouloumas,Elena Nikiphorou,Simon Stones,Tanita Christina Wilhelmer,Tanja Stamm +13 more
TL;DR: In this article, a multinational qualitative study was conducted in Austria, Croatia, Italy and the Netherlands to explore whether patient-reported outcome measures (PROMs) adequately cover the perspective of young people with inflammatory arthritis from different European countries.
Journal ArticleDOI
Coexistence of SLE, tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated?
Savvas Psarelis,Elena Nikiphorou +1 more
TL;DR: A review of the literature revealed three cases of SLE in co-existence with tuberous sclerosis, which give rise to the question of a possible common pathophysiological mechanism involving mammalian target of rapamycin (mTOR) in both diseases.
Journal ArticleDOI
The surgical treatment of rheumatoid arthritis: a new era?
TL;DR: There has been an in increase in the availability of effective biological agents for the treatment of rheumatoid arthritis as well as a shift towards early diagnosis and management of the inflammatory process.
Journal Article
Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care.
Elena Nikiphorou,Pekka Hannonen,Juha Asikainen,Jelena Borodina,Arto Kokko,Kirsi Paalanen,Tuomas Rannio,Tuulikki Sokka +7 more
TL;DR: IB was well-tolerated and comparable to IO, with no additional safety signals identified, and the results suggest superior survival of IB over IO over the first 2 years.